NL-OMON39056已完成不适用
Dendritic cell vaccination in patients with Lynch Syndrome or colorectal cancer with MSI - DC vaccination in lynch syndrome patients
niversitair Medisch Centrum Sint Radboud0 个研究点目标入组 25 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* histologically documented evidence of CRC (group I) and Lynch syndrome carrier without signs of disease (group II)
- •* HLA-A2.1 phenotype is required
- •* MSI high tumor
- •* WBC >3.0×109/l, lymphocytes >0.8×109/l, platelets >100×109/l, serum creatinine <150 µmol/l, serum bilirubin <25 µmol/l
- •* WHO performance status 0-1 (Karnofsky 100-70%)
- •* age 18-75 years
- •* expected adequacy of follow-up
- •* written informed consent
排除标准
- •* history of malignancy in the past 5 years with the exception of adequately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix
- •* serious active infections, HbsAg or HIV positive
- •* autoimmune diseases or organ allografts
- •* concomitant use of immunosuppressive drugs
- •* known allergy to shell fish
- •* pregnant or lactating women
研究者
相似试验
进行中（未招募）
1 期
Dendritic cell vaccination in patients with Lynch Syndrome or colorectal cancer with MSI - DC vaccination in lynch syndrome patientsIn this study our primary objective is to induce or enhance an immune response to tumor antigens in Lynch syndrome mutation carriers (with and without colorectal adenomas or carcinomas) and patients with sporadic colorectal cancer (CRC) showing microsatellite instability (MSI-high), the hallmark of MMR dysfunction, and test the hypothesis that DC vaccination might be effective as prophylactic treatment in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) or Lynch syndrome mutation carriers.EUCTR2008-005584-33-NLRadboud University Nijmegen Medical Centre25
进行中（未招募）
不适用
Forsøg med dendritcellevaccination i kombination med kemoterapi til behandling af patienter med prostatakræft, der har spredt sigCastration resistent metastatic prostate cancerMedDRA version: 14.1Level: HLTClassification code 10036908Term: Prostatic neoplasms malignantSystem Organ Class: 100000004864EUCTR2011-001602-10-DKCenter for Cancer Immunotherapy (CCIT) / Department of Oncology, Herlev Hospital
进行中（未招募）
不适用
Dendritic cell-based Immunotherapy in patients with primary glioblastoma multiformeNeoplasmsKCT0000280Bundang CHA General Hospital13
已完成
1 期
Clinical study of Dendritic Cell Vaccine in patients with Gastroenterological Cancer and Hepato-Biliary-Pancreatic Cancer.Esophageal cancer, Stomach cancer, Colon cancer, HCC, ICC, Bile duct cancer, pancreatic cancerJPRN-UMIN000005820Department of Gastroenterological Surgery, Tokyo Women's Medical University100
进行中（未招募）
1 期
Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSIColorectal CancerNCT01885702Radboud University Medical Center25